Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02911025 · ClinicalTrials.gov registry record
Effects of Clobazam on Sleep and Daytime Function in Patients With Epilepsy
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 13
- Enrollment target
NCT02911025: Completed study, sponsored by Brigham and Women's Hospital.
NCT02911025 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02911025 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to monitor the effect of Clobazam on sleep and daytime alertness in people with Epilepsy.
Primary Outcome
The change in total sleep time in patients with epilepsy treat with clobazam one week after reaching effective clobazam dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-12 |
What the finished NCT02911025 record still lists
NCT02911025 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02911025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02911025 about?
NCT02911025 is a clinical study titled "Effects of Clobazam on Sleep and Daytime Function in Patients With Epilepsy". The purpose of this study is to monitor the effect of Clobazam on sleep and daytime alertness in people with Epilepsy.
What is the current status of trial NCT02911025?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2015-01. Estimated completion is 2017-12.
Who is sponsoring clinical trial NCT02911025?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia